Tofacitinib Versus Biologic Treatments in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors: Results From a Network Meta-analysis

Clinical Therapeutics

Volumn 38, Issue 12, 2016, Pages 2628-2641.e5

  Vieira, Maria Cecilia ^a   Zwillich, Samuel H ^b   Jansen, Jeroen P ^c   Smiechowski, Brielan ^a   Spurden, Dean ^d   Wallenstein, Gene V ^b  

^a Mapi Group   (United States)

^b PFIZER INC   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

disease modifying antirheumatic drugs; rheumatoid arthritis; tofacitinib; tumor necrosis factor inhibitors

Indexed keywords

ABATACEPT; ADALIMUMAB; ANAKINRA; BIOLOGICAL PRODUCT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLIMUMAB; HYDROXYCHLOROQUINE; INFLIXIMAB; METHOTREXATE; PLACEBO; RITUXIMAB; SALAZOSULFAPYRIDINE; TOCILIZUMAB; TOFACITINIB; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY; PIPERIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; TUMOR NECROSIS FACTOR;

ARTICLE; BIOLOGICAL THERAPY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HEALTH ASSESSMENT QUESTIONNAIRE; HEALTH ASSESSMENT QUESTIONNAIRE DISABILITY INDEX SCORE; HUMAN; INFECTION; META ANALYSIS; MONOTHERAPY; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; SYSTEMATIC REVIEW; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; MALE; NETWORK META-ANALYSIS; TREATMENT FAILURE; TREATMENT OUTCOME;

ABATACEPT; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; DRUG THERAPY, COMBINATION; HUMANS; MALE; METHOTREXATE; NETWORK META-ANALYSIS; PIPERIDINES; PYRIMIDINES; PYRROLES; RITUXIMAB; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85006725128     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2016.11.004     Document Type: Article

References (41)

1. 1 Singh, J.A., Saag, K.G., Bridges, S.L. Jr, et al. 2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 68 (2016), 1–26.
2. 2 National Institute for Health and Clinical Excellence (NICE). National Collaborating Centre for Chronic Conditions. Rheumatoid arthritis: the management of rheumatoid arthritis in adults. 2009, NICE Clin Guide, London (UK), 79.
3. 3 Ledingham, J., Deighton, C., Update on the British Society for Rheumatology guidelines for prescribing TNFalpha blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001). Rheumatology (Oxford) 44 (2005), 157–163.
4. 4 Smolen, J.S., Landewé, R., Breedveld, F.C., et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 73 (2014), 492–509.
5. 5 Kiely, P.D., Deighton, C., Dixey, J., Ostor, A.J., Biologic agents for rheumatoid arthritis-negotiating the NICE technology appraisals. Rheumatology (Oxford) 51 (2012), 24–31.
6. 6 Rubbert-Roth, A., Finckh, A., Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review. Arthritis Res Ther, 11(Suppl 1), 2009, S1.
7. 7 Ghoreschi, K., Jesson, M.I., Li, X., et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol 186 (2011), 4234–4243.
8. 8 Meyer D, Head R, Thompson J, et al. Mechanism of action of the JAK inhibitor, CP-690550, in rheumatoid arthritis. Abstract presented at: 8th Cytokines and Inflammation Conference San Diego, California, 2010.
9. 9 Kontzias, A., Laurence, A., Gadina, M., O'Shea, J.J., Kinase inhibitors in the treatment of immune-mediated disease. F1000 Med Rep, 4, 2012, 5.
10. 10 Burmester, G.R., Blanco, R., Charles-Schoeman, C., et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet 381 (2013), 451–460.
11. 11 Fleischmann, R., Kremer, J., Cush, J., et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 367 (2012), 495–507.
12. 12 Kremer, J.M., Cohen, S., Wilkinson, B.E., et al. A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. Arthritis Rheum 64 (2012), 970–981.
13. 13 van der Heijde, D., Tanaka, Y., Fleischmann, R., et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum 65 (2013), 559–570.
14. 14 van Vollenhoven, R.F., Wallenstein, G., Lee, E.B., et al. Effects of tofacitinib (CP-690,550), an oral janus kinase lnhibitor, or adalimumab on patient reported outcomes in a phase 3 study of active rheumatoid arthritis. Ann Rheum Dis, 71, 2012, 206 Abstract.
15. 15 Lee, E.B., Fleischmann, R., Hall, S., et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med 370 (2014), 2377–2386.
16. 16 Wollenhaupt, J., Silverfield, J., Lee, E.B., et al. Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies. J Rheumatol 41 (2014), 837–852.
17. 17 Caldwell, D.M., Ades, A.E., Higgins, J.P., Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 331 (2005), 897–900.
18. 18 Hoaglin, D.C., Hawkins, N., Jansen, J.P., et al. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. Value Health 14 (2011), 429–437.
19. 19 Jansen, J.P., Fleurence, R., Devine, B., et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health 14 (2011), 417–428.
20. 20 Lu, G., Ades, A.E., Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 23 (2004), 3105–3124.
21. 21 Schoels, M., Aletaha, D., Smolen, J.S., Wong, J.B., Comparative effectiveness and safety of biological treatment options after tumour necrosis factor alpha inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis. Ann Rheum Dis 71 (2012), 1303–1308.
22. 22 Salliot, C., Finckh, A., Katchamart, W., et al. Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis. Ann Rheum Dis 70 (2011), 266–271.
23. 23 Jadad, A.R., Moore, R.A., Carroll, D., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 17 (1996), 1–12.
24. 24 University of York, Centre for Reviews and Dissemination. Systematic Reviews: CRD's Guidance for Undertaking Review in Health Care, 2008, Centre for Reviews and Dissemination, University of York, York, UK.
25. 25 Sutton, A.J., Abrams, K.R., Bayesian methods in meta-analysis and evidence synthesis. Stat Methods Med Res 10 (2001), 277–303.
26. 26 Dias S, Welton MJ, Sutton AJ, Ades AE. NICE DSU technical support document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials, 2011. http://www.nicedsu.org.uk. Accessed April 1, 2015.
27. 27 Spiegelhalter, D, Thomas, A, Best, N, Lunn, D, WinBUGS User Manual: Version 1.4, 2003, MRC Biostatistics Unit, Cambridge, UK.
28. 28 Cohen, S.B., Emery, P., Greenwald, M.W., et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 54 (2006), 2793–2806.
29. 29 Emery, P., Keystone, E., Tony, H.P., et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 67 (2008), 1516–1523.
30. 30 Genovese, M.C., Becker, J.C., Schiff, M., et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 353 (2005), 1114–1123.
31. 31 Keystone, E., Burmester, G.R., Furie, R., et al. Improvement in patient-reported outcomes in a rituximab trial in patients with severe rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. Arthritis Rheum 59 (2008), 785–793.
32. 32 Smolen, J.S., Kay, J., Doyle, M.K., et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 374 (2009), 210–221.
33. 33 Strand, V., Burmester, G.R., Ogale, S., et al. Improvements in health-related quality of life after treatment with tocilizumab in patients with rheumatoid arthritis refractory to tumour necrosis factor inhibitors: results from the 24-week randomized controlled RADIATE study. Rheumatology (Oxford) 51 (2012), 1860–1869.
34. 34 Westhovens, R., Cole, J.C., Li, T., et al. Improved health-related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti-TNF therapy in a double-blind, placebo-controlled, multicentre randomized clinical trial. Rheumatology (Oxford) 45 (2006), 1238–1246.
35. 35 Bergman, G.J., Hochberg, M.C., Boers, M., et al. Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs. Semin Arthritis Rheum 39 (2010), 425–441.
36. 36 Devine, E.B., Alfonso-Cristancho, R., Sullivan, S.D., Effectiveness of biologic therapies for rheumatoid arthritis: an indirect comparisons approach. Pharmacotherapy 31 (2011), 39–51.
37. 37 Launois, R., Avouac, B., Berenbaum, F., et al. Comparison of certolizumab pegol with other anticytokine agents for treatment of rheumatoid arthritis: a multiple-treatment Bayesian metaanalysis. J Rheumatol 38 (2011), 835–845.
38. 38 Schmitz, S., Adams, R., Walsh, C.D., et al. A mixed treatment comparison of the efficacy of anti-TNF agents in rheumatoid arthritis for methotrexate non-responders demonstrates differences between treatments: a Bayesian approach. Ann Rheum Dis 71 (2012), 225–230.
39. 39 Singh, J.A., Christensen, R., Wells, G.A., et al. A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview. CMAJ 181 (2009), 787–796.
40. 40 Turkstra, E., Ng, S.K., Scuffham, P.A., A mixed treatment comparison of the short-term efficacy of biologic disease modifying anti-rheumatic drugs in established rheumatoid arthritis. Curr Med Res Opin 27 (2011), 1885–1897.
41. 41 Cooper, N.J., Sutton, A.J., Morris, D., et al. Addressing between-study heterogeneity and inconsistency in mixed treatment comparisons: Application to stroke prevention treatments in individuals with non-rheumatic atrial fibrillation. Stat Med 28 (2009), 1861–1881.